Gilead Sciences, Inc. (ETR: GIS)
Germany flag Germany · Delayed Price · Currency is EUR
88.94
+1.26 (1.44%)
Dec 20, 2024, 5:35 PM CET

Gilead Sciences Company Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.

The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies.

The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc.
Gilead Sciences logo
Country United States
Founded 1987
Industry Drug Manufacturers - General
Sector Healthcare
Employees 18,000
CEO Daniel P. O'Day

Contact Details

Address:
333 Lakeside Drive
Foster City, Delaware 94404
United States
Phone 650 574 3000
Website gilead.com

Stock Details

Ticker Symbol GIS
Exchange Deutsche Börse Xetra
Fiscal Year January - December
Reporting Currency USD
ISIN Number US3703341046
SIC Code 2836

Key Executives

Name Position
Daniel P. O'Day Chairman and Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Deborah H. Telman J.D. Executive Vice President of Corporate Affairs, General Counsel and Corporate Secretary
Johanna Mercier Chief Commercial Officer
Dr. Merdad V. Parsey M.D., Ph.D. Chief Medical Officer
Sandra Patterson Senior Vice President, Corporate Controller and Principal Accounting Officer
Jacquie Ross C.F.A. Vice President of Investor Relations
Jyoti K. Mehra Executive Vice President of Human Resources
Dr. Linda Slanec Higgins Ph.D. Senior Vice President of Research, Innovation and Portfolio
Dr. Rudolf Ertl Senior Vice President of Commercial Operations of Australia, Canada, Europe